Document resource
The study by Lakhani et al 1 scrutinises data from the US Food and Drug Administration (FDA) Adverse Event Reporting System, revealing formulation and sex-specific associations of the anti-obesity medication (AOM) with ischaemic optic neuropathy (ION). Interestingly, higher odds were associated with males (reporting odds ratio (ROR) 116.37), with greater risks from Wegovy which is used for obesity treatment (ROR 74.89), compared with Ozempic which is used for diabetes (ROR 18.81). These findings add to an emerging body of growing literature reporting ocular complications with AOMs2 which warrants further scrutiny and urgent clarification for ophthalmologists.